Use of GNRH antagonists in reproductive medicine

Minerva Ginecologica

Volumn 57, Issue 1, 2005, Pages 29-43

  Merviel, P ^a   Najas, S ^a   Campy, H ^a   Floret, S ^a   Brasseur, F ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Folliculogenesis; GnRH agonist; GnRH antagonist; LH; Pregnancy rate

Indexed keywords

BUSERELIN; CETRORELIX; CLOMIFENE; ESTRADIOL; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; NOMEGESTROL ACETATE; NORETHISTERONE; TRIPTORELIN; DRUG DERIVATIVE; GONADORELIN;

CLINICAL TRIAL; COHORT ANALYSIS; CRYOPRESERVATION; DRUG ACTIVITY; DRUG MECHANISM; EMBRYO DEVELOPMENT; EMBRYO TRANSFER; ENDOMETRIUM; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; INTRAUTERINE INSEMINATION; OOCYTE MATURATION; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION; PHYSICIAN; PREGNANCY RATE; REVIEW; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FEMALE INFERTILITY; METHODOLOGY; OOCYTE; PREGNANCY; REPRODUCTION;

FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; OOCYTES; PREGNANCY; REPRODUCTIVE MEDICINE;

EID: 20644464337     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Karten MJ, Hoeger CA, Hooh WA, Lindberg MC, Nagvi R. The development of safer antagonists: strategy and status, recent progress on GnRH and Gonadal peptides. In: Bouchard P, Haour F, Franchimont P, Schatz B, editors. Paris: Elsevier; 1990. Session II: p. 147-58.
2. Bouchard P, Charbonnel B, Caraty A, Fraser HM, Dubourdieu S, Leroy I et al. The role of GnRH during the periovulatory period: a basis for the use of GnRH antagonists in ovulation induction. In: Filicori M, Flamigni C, editors. Ovulation: Basic Science and Clinical Advances. Paris: Elsevier Science; 1994. BV International Congress Series 1046.
3. Frydman R, Cornel C, De Ziegler D, Taieb J, Spitz IM, Bouchard P. Prevention of premature luteinizing hormone and progesterone rise with a GnRH antagonist Nal-Glu in controlled ovarian hyperstimulation. Fertil Steril 1991;56:923-7.
4. Diedrich K, Diedrich E, Santos E, Zoll C, al-Hasani S, Reissmann T et al. Suppression of the endogenous LH-surge by the GnRH-antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994;9:788-91.
5. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotrophin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997;67:917-22.
6. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a new GnRH antagonist (Cetrorelix) in IVF-ET with a single dose protocol: a dose finding study of 3 versus 2 mg. Hum Reprod 1998;13:2411-4.
7. The Ganerelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist Ganirelix (Org 37 462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998;13:3023-31.
8. Olivennes F, Fanchin R, Bouchard P, Taieb J, Selva J, Frydman R. Scheduled administration of GnRH agonist (Cetrorelix) on day 8 of in vitro fertilization cycles: a pilot study. Hum Reprod 1995;10:1382-6.
9. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (tryptorelin). Fertil Steril 2000;73:314-20.
10. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winsen H, Engel J, Diedrich K et al. Controlled ovarian stimulation with hMG: results of a prospective randomized phase III European study comparing the LHRH-antagonist Cetrorelix (Cetrotide) and the LHRH-agonist Buserilin. Hum Reprod 2000;15:526-31.
11. Mannaerts B, Borm G, European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000;15:1490-8.
12. Felberbaum RE, Albano C, Ludwig M, Riethmuller-Winzen H, Grigat M, Devroey P. Ovarian stimulation for assisted reproduction with HMG and concomitant mid-cycle administration of the LHRH-antagonist Cetrorelix (Cetrotide) according to the multiple dose protocol - results of a prospective non controlled phase III study. Hum Reprod 2000;15:1015-20.
13. Dubourdieu S, Le Nestour E, Spitz IM, Charbonnel B, Bouchard P. The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation. Hum Reprod 1993;8:2056-60.
14. De Jong D, Macklon NS, Mannaerts B, Coelingh-Bennink HJ, Fauser BC. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in vitro fertilization. Hum Reprod 1998;13:573-5.
15. Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2001;4:CD001750.
16. D'Amato G, Caroppo E, Pasquadibisceglie A, Carone D, Vitti A, Vizziello GM. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years. Fertile Steril 2004;81:1572-7.
17. Weghofer A, Margreiter M, Bassim S, Sevelda U, Beilhack E, Feichtinger W. Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age. Fertil Steril 2004;81:1002-6.
18. Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in in vitro fertilization. Fertile Steril 1998;69:419-24.
19. Cedrin-Durnerin I, Bulwa S, Herve F, Martin-Pont B, Uzan M, Hugues JN. The hormonal flare-up following gonadotrophin-releasing hormone agonist administration is influenced by a progestogen pretreatment. Hum Reprod 1996;11:1035-7.
20. Fanchin R, Cunha-Filho JS, Schonauer LM, Righini C, de Ziegler D, Frydman R. Luteal estradiol administration strengthens the relationship between day 3 follicle-stimulating hormone and inhibin B levels and ovarian follicular status. Fertil Steril 2003;79:585-9.
21. Cassidenti DL, Sauer MV, Paulson RJ, Ditkoff EC, Rivier J, Yen SS et al. Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (nal-Glu) in in vitro fertilization cycles: a preliminary report. Am J Obstet Gynecol 1991;165:1806-10.
22. Shapiro DB, Mitchell-Leef D. GnRH antagonist in in vitro fertilization: wher we are now. Minerva Ginecol 2003;55:373-88.
23. Copperman AB. Antagonists in poor-responders patients. Fertil Steril 2003;80:S16-24.
24. Emperaire JC, Parneix I, Perraguin-Jayot S. Revisiting the clomifene-gonadotropin protocol in IVF with the use of a GnRH antagonist. Gynecol Obstet Fertil 2003;31: 927-31.
25. Ludwig M, Albano C, Olivennes F, Felberbaum RE, Smitz J, Ortmann O et al. Plasma and follicular fluid concentration of LHRH antagonist cetrorelix (cetrotide) in controlled ovarian stimulation for IVF. Arch Gynecol Obstet 2002;266:12-7.
26. Escudero E, Bosch E, Crespo J, Simon C, Remohi J, Pellicer A. Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients. Fertil Steril 2004;81:562-6.
27. FIVNAT, Pouly JL, Bachelot A, de Mouzon J, Devaux A. Comparison of agonists versus antagonists for IVF stimulation: the French FIVNAT survey 2001-2002. Gynecol Obstet Fertil 2004;32:737-40.
28. Devaux A, Pouly JL, Bachelot A, Mourouvin Z, de Mouzon J. Biological effects of GnRH antagonists. Gynecol Obstet Fertil 2004;32:741-7.
29. Hernandez RE. Embryo implantation and GnRH antagonists. Hum Reprod 2000;15:1211-6.
30. Del Gadillo JC, Siebzchnrubl E, Dittrich R, Wildt L, Lang N. Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: a matched study. Eur J Obstet Gynecol Reprod Biol 2002;102:179-83.
31. Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R. The use of GnRh antagonists in ovarian stimulation. Hum Reprod 2002;8:279-90.
32. Ricciarelli E, Sanchez M, Martinez M, Andres L, Cuadros J, Hernandez ER. Impact of the gonadotrophin-releasing hormone antagonist in oocyte donation cycles. Fertil Steril 2003;79:1461-3.
33. Fluker M, Grifo J, Leader A, Meldrum D, Muasher SJ, Rinehart J et al. Efficacy and safety of Ganirelix acetate versus Leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75: 38-45.
34. Tavaniotou A, Albano C, Smitz J, Devroey P. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Hum Reprod 2001;16:663-7.
35. Gordon K. Gonadotropin-releasing hormone antagonists implications for oocyte quality and uterine receptivity. Ann NY Acad Sci 2001;943:49-54.
36. Clifford K, Rai R, Watson H. Does suppressing luteinizing hormone secretion reduce the miscarriage rate? Results of a randomized controlled trial. BMJ 1996;312: 1508-11.
37. Kolibianakis EM, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steiteghem A et al. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin-releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 2002;78:1025-9.
38. Merviel P, Antoine JM, Mathieu E, Millot F, Mandelbaum J, Uzan S. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer. Fertil Steril 2004;82:119-25.
39. Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF, Pavlou SN. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hypertsimulation: cycle performance and in vitro steroidogenesis of granulosalutein cells. Am J Obstet Gynecol 1995;172:1518-25.
40. Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod 1998;13:1788-92.
41. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normo gonadotrophic women undergoing assisted reproduction. Hum Reprod 2000;15:1003-8.
42. Aboulghar MA, Mansour RT, Serour GI, Al-Inany HG, Amin YM, Aboulghar MM. Increasing the dose of human menapausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial. Reprod Biomed Online 2004;8:524-7.
43. Wikland M, Bergh C, Borg K, Hillensjo T, Howles CM, Knuttson A et al. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for FIV/ICSI. Hum Reprod 2001;16:1676-81.
44. Seelig AS, Al Hasani S, Katalinic A, Schopper B, Sturm R, Diedrich K et al. Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril 2002;77:472-5.
45. Asimakopoulos B, Nikolettos N, Al-Hasani S. Outcome of cryopreserved pronuclear oocytes obtained after stimulation with either HMG or recFSH and the GnRH-antagonist cetrorelix. Reprod Biomed Online 2002;5:52-6.
46. Olivennes F, Diedrich K, Frydman R, Felberbaum RE, Howles CM. Cetrotide International Study Group. Safety and efficacy of a 3 mg dose of GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online 2003;6:432-8.
47. Lindheim SR, Morales AJ. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod 2003;18: 2048-51.
48. Giorgetti C, Terriou P, Auquier P, Hans E, Spach J, Salzmann J et al. Embryo score to predict implantation after in vitro fertilization: based on 957 single embryo transfers. Hum Reprod 1995;10:2427-31.
49. Roulier R, Chabert-Orsini V, Sitri MC, Barry B, Terriou P. Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix 3 mg) in patients undergoing assisted reproduction treatment. Reprod Biomed Online 2003;7:185-9.
50. Albano C, Grimbizis G, Smitz J, Riethmuller-Winsen H, Reissmann T, Van Steirteghem A et al. The luteal phase of non supplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 1998;70:357-9.
51. Ragni G, Vegetti W, Baroni E, Colombo M, Arnoldi M, Lombroso G et al. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Hum Reprod 2001;16:2258-62.
52. Merviel P, Evain-Brion D, Challier JC, Salat-Baroux J, Uzan S. The molecular basis of embryo implantation in humans. Zentralbl Gynakol 2001;123:328-39.
53. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem A, Devroey P. Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab 2003;88:5632-7.
54. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem A, Devroey P. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 2004;82:102-7.
55. Rongieres-Bertrand C, Olivennes F, Righini C, Fanchin R, Taieb J, Hamamah S et al. Revival of the natural cycles in in vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod 1999;14:683-8.
56. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 1990;71:918-22.
57. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J et al. Endocrine profiles after triggering of final oocyte maturation with GnRH antagonist Ganirelix during ovarian hyperstimulation. J Clin Endocrinol Metab 2002;87:709-15.
58. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004;81:1-5.
59. Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation with a GnRH agonist in patient pretreated with a GnRH antagonist: a pilot study. Fertil Steril 1996;66:151-3.
60. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix tretament in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Hum Reprod 2000;15:1965-8.
61. Ludwig M, Riethmüller-Winzen H, Felberbaum RE, Olivennes F, Albano C, Devroey P et al. Health of 227 children born after ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix. Fertil Steril 2001;75:18-22.
62. Van den Dungen HM, van Dielen JA, Tilders FJ, van Rees GP, Schoemaker J. Administration of a GnRH-antagonist to immature rats affects subsequent female and male pubertal development differently. Acta Endocrinol (Copenh) 1989;120:778-84.